Ask Anything

Jörg Hausleiter

2w

“

Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention.

“

By moving beyond visual estimation alone, this approach brings complete revascularization closer to precision medicine: treating the lesions that matter, while avoiding unnecessary PCI in lesions that do not appear to limit blood flow. These results support functional coronary angiography as a ne...

“

The risk of heart attack and stroke is a concern for older people and knowing there is an effective measure for lowering that risk will be a huge reassurance to older people and their families. We hope to see updated guidelines to help clinicians make use of these new findings.

Viktor Kočka

2w

“

In contrast to interventions for myocardial infarction or stroke, there have been very few advances in the treatment of [PE] over the last 20 years. This has led to a considerable unmet clinical need that we can't ignore.

“

For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease.

Dr. Rolf Wachter

Professor of Clinical and Interventional Cardiology · Leipzig University

2w

“

Our data show that most of the improvement reported by patients does not appear to be attributable to catheter ablation itself, but rather to factors such as a placebo effect or adjustments to their medication. Current guidelines recommend catheter ablation primarily to prevent the recurrence of atrial fibrillation and improve quality of life. However, our study shows that the effect of the ablation itself does not adequately explain the improvement in quality of life.

“

“Despite major advances in pharmacologic and device-based therapies, pulmonary hypertension remains one of the strongest predictors of hospitalization, right ventricular failure, and death in patients with left heart disease and heart failure.”

“

Importantly, this was not because coronary access was impaired after TAVI. Rather, once the valve had been treated, the clinical decision about whether PCI was still necessary sometimes changed.

“

“Why is this important in terms of safety? Because milvexian is currently being evaluated in two other large trials: one in atrial fibrillation and one in secondary stroke prevention.”

Mathew Maurer

Professor of Cardiology, Columbia University Irving Medical Center · Columbia University Irving Medical Center

16h

“

In CARDIO-TTRansform, the largest ATTR-CM trial to date, eplontersen achieved reductions in circulating serum TTR, although the trial did not demonstrate a significant reduction in the primary endpoint in the overall population. Baseline stabilizer use appeared to influence the primary results. No additional benefit was observed in patients receiving background stabilizer therapy, while fewer primary endpoint events were observed with eplontersen in patients not receiving a stabilizer.

Read the full quote